eFT226-0002 (Effector Therapeutics)
Description: A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with Selected Advanced Solid Tumor Malignancies
Mechanism of Action: eFT226 is a potent and selective inhibitor of translation of select mRNAs
Target Population: . ER positive breast cancer with FGFR amplifications, and NSCLC with KRAS G12C mutations (in combination with Sotorasib)
Study Design: In Dose Escalation Study drug is administered IV weekly.